BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26942060)

  • 1. Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.
    Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
    Oncoimmunology; 2016; 5(1):e1052213. PubMed ID: 26942060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases.
    Ferns DM; Heeren AM; Samuels S; Bleeker MCG; de Gruijl TD; Kenter GG; Jordanova ES
    J Immunother Cancer; 2016; 4():78. PubMed ID: 27895918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.
    Bijen CB; Bantema-Joppe EJ; de Jong RA; Leffers N; Mourits MJ; Eggink HF; van der Zee AG; Hollema H; de Bock GH; Nijman HW
    Int J Cancer; 2010 Mar; 126(6):1417-27. PubMed ID: 19728333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
    Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
    Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
    Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
    Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.
    Babay W; Ben Yahia H; Boujelbene N; Zidi N; Laaribi AB; Kacem D; Ben Ghorbel R; Boudabous A; Ouzari HI; Rizzo R; Rebmann V; Mrad K; Zidi I
    Hum Immunol; 2018 Jun; 79(6):463-470. PubMed ID: 29499226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers.
    Rangel LB; Agarwal R; Sherman-Baust CA; Mello-Coelho Vd; Pizer ES; Ji H; Taub DD; Morin PJ
    Cancer Biol Ther; 2004 Oct; 3(10):1021-7. PubMed ID: 15467430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of HLA-DR antigen in serous ovarian tumors.
    Tamiolakis D; Kotini A; Venizelos J; Jivannakis T; Simopoulos C; Papadopoulos N
    Clin Exp Med; 2003 Sep; 3(2):113-8. PubMed ID: 14598186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
    Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
    J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
    Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
    Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesion HLA-G5/-G6 isoforms expression in patients with ovarian cancer.
    Zhang X; Han QY; Li JB; Ruan YY; Yan WH; Lin A
    Hum Immunol; 2016 Sep; 77(9):780-4. PubMed ID: 26687271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of HLA-E expression in human tumors.
    Marín R; Ruiz-Cabello F; Pedrinaci S; Méndez R; Jiménez P; Geraghty DE; Garrido F
    Immunogenetics; 2003 Feb; 54(11):767-75. PubMed ID: 12618909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-E expression and its clinical relevance in human renal cell carcinoma.
    Seliger B; Jasinski-Bergner S; Quandt D; Stoehr C; Bukur J; Wach S; Legal W; Taubert H; Wullich B; Hartmann A
    Oncotarget; 2016 Oct; 7(41):67360-67372. PubMed ID: 27589686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients.
    de Kruijf EM; Sajet A; van Nes JG; Natanov R; Putter H; Smit VT; Liefers GJ; van den Elsen PJ; van de Velde CJ; Kuppen PJ
    J Immunol; 2010 Dec; 185(12):7452-9. PubMed ID: 21057081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype.
    Ibrahim EC; Aractingi S; Allory Y; Borrini F; Dupuy A; Duvillard P; Carosella ED; Avril MF; Paul P
    Int J Cancer; 2004 Jan; 108(2):243-50. PubMed ID: 14639610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
    Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
    Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
    Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between HLA-expression and infiltration of immune cells in cervical carcinoma.
    Hilders CG; Houbiers JG; van Ravenswaay Claasen HH; Veldhuizen RW; Fleuren GJ
    Lab Invest; 1993 Dec; 69(6):651-9. PubMed ID: 8264228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β.
    Ullah M; Azazzen D; Kaci R; Benabbou N; Pujade Lauraine E; Pocard M; Mirshahi M
    Neoplasia; 2019 Mar; 21(3):331-342. PubMed ID: 30802770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.